Crescendo Biologics clinches deal with Cancer Research UK
Cambridge-based Crescendo Biologics has signed a deal with Cancer Research UK in a move to target cancers of high unmet medical need.
The clinical development partnership is designed to progress one of Crescendo’s novel bispecific Humabody® immunotherapies, CB213, into clinical trials.
Privately owned Crescendo, based at Babraham Research Campus, develops novel, targeted, T cell enhancing therapeutics.
Cancer Research UK’s Centre for Drug Development will sponsor and fund a future Phase I clinical trial for CB213, in patients with solid tumours.
Crescendo retains the right to further develop the CB213 immunotherapy programme by licensing the results of the trial from Cancer Research UK for an undisclosed amount, success-based milestones and royalty payments.
CB213, a novel bispecific PD-1 x LAG-3 antagonist, is a next-generation checkpoint inhibitor, which has been designed to deliver safer, more effective therapeutic intervention in patients with cancers resistant or refractory to PD-1 blockade alone.
In preclinical testing, CB213 has demonstrated potent dual checkpoint blockade and the ability to enhance the activity of dysfunctional patient-derived T cells.
Crescendo Biologics CEO Theodora Harold said: “Cancer Research UK’s endorsement of our science demonstrates important validation of our Humabody technology and provides an opportunity to accelerate our CB213 programme into the clinic. CB213 is a promising therapeutic candidate for treating patients with solid tumours, where conventional or combination immunotherapies have failed.”
Dr Nigel Blackburn, Cancer Research UK's Director of Drug Development, added: “We’re proud to be working with Crescendo at the forefront of oncology innovation and cancer drug development.
“By combining our expertise, we’re able to accelerate the development of this promising experimental treatment, bringing it to patients with cancers that are hard to treat.”